SCHEMBL3658261

SCHEMBL3658261

COc1ccc(F)cc1CC(=O)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
CYP3A4 P08684 2/20 0.43
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.42
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
TSPO P30536 2/20 0.41
CSNK1D P48730 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29531411 0.88 SMN1; SMN2 (0.48) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL17652108 0.88 SMN1; SMN2 (0.48) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL3659915 0.86 HSD17B10 (0.50) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL6343545 0.84 HSD17B10 (0.70) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL10864128 0.84 CYP3A4 (0.62) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL29431167 0.84 HSD17B10 (0.70) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL23362766 0.83 SMN1; SMN2 (0.52) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL3876888 0.83 MEN1 (0.51) HSD17B10SMN1; SMN2ALDH1A1GAAMEN1
SCHEMBL892777 0.83 HSD17B10 (0.73) HSD17B10MEN1KMT2A
SCHEMBL30660236 0.83 HSD17B10 (0.73) HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022257894-A1 P300 INHIBITOR AND PHARMACEUTICAL USE THEREOF 贝达药业股份有限公司 2022-12-15 WO disclosed
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 HSD17B10 1336/4885SMN1; SMN2 3920/4885ALDH1A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.